Home › Funds › Soleus Capital Management, L.P. › JBIO
Soleus Capital Management, L.P. position in JBIO
JADE BIOSCIENCES INC · Health Care
Soleus Capital Management, L.P. reported holding 1,170,928 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$16.5M, representing 0.58% of its reported portfolio and ranking #40 among its reported holdings. Soleus Capital Management, L.P. has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s JBIO position evolved
Soleus Capital Management, L.P. first disclosed a stake in JBIO in Q2 2025 at 796,744 shares (US$8.0M). The position peaked in Q2 2026 at 1,550,690 shares, worth US$34.5M. Across 6 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,170,928 shares valued at US$16.5M — a reduction of -379,762 shares quarter over quarter.. Notable position changes include a 95% increase in Q2 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 796.74K | $7.96M | New |
| Q3 2025 | 796.74K | $6.88M | Hold |
| Q4 2025 | 796.74K | $12.29M | Hold |
| Q1 2026 | 796.74K | $11.19M | Hold |
| Q2 2026 | 1.55M | $34.46M | Add |
| Q3 2026 | 1.17M | $16.45M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 81 other funds we track also report a position in JBIO — the largest reported positions include Paradigm Biocapital Advisors LP (US$85.0M), Fairmount Funds Management LLC (US$64.0M), Bellevue Group AG (US$60.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Paradigm Biocapital Advisors LP 6.05M sh · $85.05M · Q3 2026
- Fairmount Funds Management LLC 4.55M sh · $63.98M · Q3 2026
- Bellevue Group AG 4.29M sh · $60.33M · Q3 2026
- Venrock Adviser, LLC 3.22M sh · $45.25M · Q3 2026
- Avidity Partners Management LP 2.00M sh · $28.10M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 1.84M sh · $25.79M · Q3 2026
- Remedium Capital Partners, LLC 1.81M sh · $25.40M · Q3 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $17.29M · Q3 2026
- Versant Venture Management, LLC 991.78K sh · $13.93M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $13.86M · Q3 2026
- Foresite Capital Management VI LLC 886.67K sh · $12.46M · Q3 2026
- Affinity Asset Advisors, LLC 760.35K sh · $10.68M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held JBIO?
Soleus Capital Management, L.P. has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Soleus Capital Management, L.P.'s current position in JBIO?
As of Q3 2026, Soleus Capital Management, L.P. holds 1.17M shares of JBIO (JADE BIOSCIENCES INC), valued at $16.45M, representing 0.58% of its reported portfolio and ranking #40.
Has Soleus Capital Management, L.P. been buying or selling JBIO?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. reduced its position in JBIO. The position peaked in Q2 2026 at 1.55M shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Paradigm Biocapital Advisors LP, Fairmount Funds Management LLC, Bellevue Group AG, among 81 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.